The Crystalens AO has prolate aspheric surfaces and is designed to be free of spherical aberration and is intended to improve retinal image quality without compromising depth of field, according to the release.
Crystalens is the only FDA-approved accommodating intraocular lens. Unlike a standard cataract replacement lens, Crystalens is designed to not only eliminate a patient’s cataract but to improve the patient’s range of vision.
Although aspheric optics traditionally reduce field of vision because they have negative spherical aberration, the Crystalens AO does not reduce field of vision because it provides zero spherical aberration, according to the release.
The Crystalens AO is comprised of proprietary biosil silicone and has a thin and uninterrupted barrier edge. It will be inserted using the CI-28 injector in a controlled manner through an un-enlarged phaco incision.
Read Bausch & Lomb’s release on Crystalens AO.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
